SGimvesting
@sgunderbarth
Followers
2K
Following
58K
Media
2K
Statuses
16K
COVAXIN/OCU500 supporter and stakeholder. Let’s cure some blindness too, maybe rebuild some cartilage. Here for satire with a side of facts. HOLDING
Joined December 2012
$OCGN "To those who cannot read this with their eyes — this message is for you. Science is fighting for your light... You are not forgotten." NR2E3: The Enforcer of Retinal Stability https://t.co/rXGwTnBMkb
linkedin.com
A Mutation-Agnostic Therapy That May Stop Degeneration at Its Source Dayton, OH — For decades, retinal degeneration has been a falling‑dominoes disease: once the first gene fails, the rest collapse...
0
7
35
Today is International Day of Women and Girls in Science. Let’s work together to build a bright future for women and girls in STEM, celebrating those driving discovery today while encouraging the next generation of female scientists. #February11 #CourageousInnovation
1
8
55
CSO Arun Upadhyay shares how gene-agnostic modifier therapies could become a leading paradigm for treating major blindness diseases, providing the opportunity to expand patient access for IRDs in @Citeline's Scrip Asks…What Does 2026 Hold for Biopharma?🔗 https://t.co/e0qs24rS6Q
0
18
91
Ms. Rita Johnson Greene, eloquent 🔥 Both US/EU Regulatory initiatives driving #CGT for equitable access for patients. https://t.co/W4CMo6fzgd
https://t.co/UnNLcHJNMf
https://t.co/kaNW4z27nL
#OCU400 $OCGN
0
5
20
Today, we welcome Rita Johnson-Greene as our new CFO. With over 20 years of healthcare experience, her deep expertise in cell and gene therapy will be vital as we enter a transformative time, beginning with the submission of the 1st of 3 BLAs this year. 🔗 https://t.co/uXahcvsSwb
0
21
121
👏👏👏
This week is #PatientRecognitionWeek. Hear from Aiden, an #OCU410ST Phase 1 participant diagnosed with #Stargardtdisease in high school. After treatment, he’s now experiencing positive changes in daily life and greater confidence. Hope begins here: https://t.co/IOI7P3xt3W
1
3
21
Wonderful news to see Congress pass legislation that reauthorizes the Rare Pediatric Disease Priority Review Voucher (PRV) program included in the Give Kids a Chance Act! #BIOTechCaucus #GiveKidsaChance
1
23
98
$OCGN if you’re wondering what happened today, it looks like there were more buyers than sellers.
1
2
19
@CGT_Live highlights published Phase 1 results for #OCU410ST. Data shows meaningful visual & structural benefits in #Stargardtdisease, including +6 letters BCVA gain in treated eyes vs −1.5 letters in untreated eyes, and no serious adverse events. Read:
cgtlive.com
The therapy provided a +6-letter gain in BCVA-evaluable patients.
With regard to safety, there were no serious adverse events (AEs) or AEs of special interest deemed related to OCU410ST reported. #Stargardt #StargardtDisease #genetherapy #Ocugen @Ocugen $OCGN Read more: https://t.co/O2bnzB8Zzr
0
23
96
$OCGN First patient for the OCU400 trial was dosed June 20th 2024, a year and 7M ago. They already have 12M results for everyone they dosed in that 1st 7months. So by the time dosing is complete, we should already be getting preliminary 12M data for about half the patients 🤔🎉
0
5
50
12-month Phase 1 data of #OCU410 for #geographicatrophy (GA) showed 60% slower ellipsoid zone loss and 20.2% reduction in GA lesion growth in treated eyes vs untreated eyes. Safety remains favorable with no serious adverse events reported. Read more: https://t.co/SAoXizc7uG
0
27
149
This is why I hold. 👏👏👏
31 years after her #retinitispigmentosa diagnosis, Nancy is experiencing change through treatment in the #OCU400 clinical trial. She reports better definition, improved light adaptation, and can read without a magnifier. Modifier gene therapy: https://t.co/OXzETxjDpJ
1
5
57
Random Friday ot rant incoming… I have “left leaning” friends and family who need to embrace what @nickshirleyy is saying. Many of you share “republican” views, which is really just basic logic and ethics in 2026. Although, you refuse to admit it. Covid lockdowns and mandates
“What’s one belief about the world that you had that you no longer hold.” NICK SHIRLEY: “Now I do believe for certain that there is brainwashing. We’re seeing real brainwashing in real time..” He’s right!! 💯👇🏼
1
2
23
$OCGN impeccable timing
Patients join our clinical trials or EAP with a clear goal: to retain or improve vision. @davidalmeidaMD shares how we support patients and how our novel modifier gene therapies aim to address the entire disease with a single, one-time treatment. 📧clinical.request@ocugen.com
2
4
41